Corporate Tech Investors

UCB S.A.

UCB S.A. is a corporate venture capital group that partners with startup ventures that can advance its organizational interests.

Venture Investor Overview

Contact Information

Background Information

Overview

UCB S.A., a biopharmaceutical company, discovers and develops therapies primarily for central nervous system (CNS) disorders and immunology diseases worldwide. Its CNS products include Vimpat and Keppra for epilepsy, and Neupro for Parkinson's disease and restless legs syndrome; Nootropil for regulating cerebral functions; and Metadate CD for attention deficit hyperactivity disorder.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

6/7/2022

Transaction History

Our records indicate that UCB S.A. invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

Jean-Christophe Tellier

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

UCB S.A. has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Ubisoft | UCHealth

Share this article

About Our Corporate Tech Investor Database

This corporate tech investor profile is powered by VentureDeal.com, a leading supplier of corporate VC funding data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary